510(k) device
SeptiCyte RAPID
Immunexpress, Inc. · Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE, Class II) · First FDA decision Nov 29, 2021, newest Dec 15, 2023Sepsis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "SeptiCyte RAPID"
MAUDE reports
0
Brand "SeptiCyte RAPID", since 2015
PubMed studies
18
Mentioning "SeptiCyte RAPID"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SeptiCyte RAPID
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- SeptiCyte RAPID510(k)
K232095 · Decided Dec 15, 2023 · 155 days after receipt
Device type: Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE) · Laboratory Medicine & Pathology
- SeptiCyte RAPID510(k)
K203748 · Decided Nov 29, 2021 · 341 days after receipt
Device type: Rt-Qpcr Assay For Mrna Transcript Immune Biomarkers (PRE) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40470WPS Insurance CorporationUpdated Sep 17, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40429Palmetto GBAUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40433CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaProposed local determinationProposedDL40435Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "SeptiCyte RAPID", any status and sponsor, newest update first.
No registered device study names "SeptiCyte RAPID".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SeptiCyte RAPID", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PRE
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SeptiCyte RAPID"[tiab]. The summary above synthesizes these.
- Rapid and Robust Identification of Sepsis Using SeptiCyte RAPID in a Heterogeneous Patient Population.
Balk R, Esper AM, Martin GS, et al. · J Clin Med · 2024
- Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test.
Gravrand V, Mellot F, Ackermann F, et al. · Viruses · 2023Research Support, U.S. Gov't, P.H.S.
- Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients.
Montero MM, Hardy-Werbin M, Gonzalez-Gallardo S, et al. · Sci Rep · 2023Research Support, U.S. Gov't, Non-P.H.S.
- Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic Inflammation.
Balk R, Esper AM, Martin GS, et al. · J Clin Med · 2024
- SeptAsTERS- SeptiCyte® RAPID as assessment tool for early recognition of sepsis - a prospective observational study.
von der Forst M, Back L, Tourelle KM, et al. · Infection · 2025Observational Study
- Likelihood of blood culture positivity using SeptiCyte RAPID.
Navalkar K, Wheelock A, Gregory M, et al. · medRxiv · 2025Preprint
- Integrating omics techniques and culture-independent systems may improve the detection of persistent candidemia: data from an observational study.
Peri AM, O'Callaghan K, Rafiei N, et al. · Ann Clin Microbiol Antimicrob · 2024Observational Study, Multicenter Study
- Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyte® RAPID in Post-Cardiac Surgery Patients: Pilot Case Series.
Risso C, Vay L, Sciascia F, et al. · Int J Mol Sci · 2025
- Diagnostic performance of SeptiCyte RAPID in critically ill patients with occlusive acute mesenteric ischemia: a pilot study.
Novy E, Cesarini D, Luc A, et al. · J Crit Care · 2025Letter
- Likelihood of Blood Culture Positivity Using SeptiCyte RAPID.
Navalkar KA, Wheelock A, Gregory M, et al. · J Clin Med · 2026
- Diagnostic accuracy of SeptiCyte® RAPID to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at ICU admission.
Cantón-Bulnes ML, García-Garmendia JL, Estella Á, et al. · Eur J Clin Microbiol Infect Dis · 2026Observational Study, Multicenter Study
- Host response signature trends in persistent bacteraemia and metastatic infection due to Staphylococcus aureus and Gram-negative bacilli: a prospective multicentre observational study.
Peri AM, Rafiei N, O'Callaghan K, et al. · Infect Dis (Lond) · 2024Observational Study, Multicenter Study
Other devices of this type
Also filed under product code PRE.
- TriVerityInflammatix, Inc. · 510(k) 2025
- SeptiCyte LABImmunexpress, Inc. · 510(k) 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.